Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Etrolizumab vs Adalimumab and Placebo in TNF-naive Moderate to Severe Ulcerative Colitis
2013-004277-27Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Etrolizumab in autoimmune colitis (3 arms), sponsored by Roche. Primary endpoint: Induction of remission vs placebo at Week 10. Started Jul 2014; status: completed.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-004277-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004277-27.